Cipla Ltd.

Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has partnered with Cipla to work on development of anti- viral drugs to contain COVID-19. Research on anti-viral drugs has been on throughout the world for long and many companies have developed molecules having anti-viral properties. But due to lack of demand, these molecules were not widely marketed. However, the CSIR-IICT decided to work on three such molecules -- remdesivir, favipiravir and baloxavir.

Cipla urged the IICT director S Chandrasekhar to start work on these molecules on an immediate basis. Cipla would upscale the process on the basis of know-how given by CSIR-IICT.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.